Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.58 |
| ▸ | CCR1 | P32246 | 2/20 | 0.58 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554984 | 0.94 | PKM (0.56) | CCR2CCR1CACNA1HCACNA1BPKM | |
| SCHEMBL3554494 | 0.92 | PKM (0.56) | CCR2CCR1CACNA1HCACNA1BPKM | |
| SCHEMBL3561665 | 0.90 | CACNA1H (0.58) | CACNA1HCACNA1BPKMSLC16A3AR | |
| SCHEMBL3563406 | 0.90 | CACNA1H (0.52) | CCR2CCR1CACNA1HCACNA1BPKM | |
| SCHEMBL3552318 | 0.89 | GFER (0.56) | CACNA1HCACNA1BPKMSLC16A3AR | |
| SCHEMBL3558860 | 0.89 | WDR5 (0.57) | CACNA1HCACNA1BPKMSLC16A3TDP1 | |
| SCHEMBL3565335 | 0.89 | CACNA1H (0.53) | CACNA1HCACNA1BPKMSLC16A3TDP1 | |
| SCHEMBL3562888 | 0.89 | SLC16A3 (0.64) | CACNA1HCACNA1BPKMSLC16A3TDP1 | |
| SCHEMBL3563754 | 0.88 | CACNA1H (0.51) | CCR2CCR1CACNA1HCACNA1BPKM | |
| SCHEMBL3558807 | 0.87 | TDP1 (0.56) | CACNA1HCACNA1BPKMSLC16A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | CCR2 1793/4885CCR1 660/4885CACNA1H 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.